Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?

Zuzda, Konrad; Grycuk, Wiktoria; Małyszko, J.; Małyszko, Jolanta

doi:10.1080/14728222.2022.2161887

Cited by 3 publications

(2 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst dyslipidemia is already present in the majority of patients, the immunosuppressive therapy often triggers the development of dyslipidemia among unaffected solid organ recipients. In this context, HDL may slightly decrease, whereas triglyceride-rich VDL and LVDL particles strongly increase causing atherosclerosis [104,105]. Therefore, solid organ recipients are usually recommended to adhere to a low-fat and low-cholesterol diet [79,95].…”

Section: Cardiovascular Risk Reduction In the Long-term Maintenance P...mentioning

confidence: 99%

Fueling the success of transplantation through nutrition: recent insights into nutritional interventions, their interplay with gut microbiota and cellular mechanisms

Koehler,

Späth,

Meyer

et al. 2024

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of review The role of nutrition in organ health including solid organ transplantation is broadly accepted, but robust data on nutritional regimens remains scarce calling for further investigation of specific dietary approaches at the different stages of organ transplantation. This review gives an update on the latest insights into nutritional interventions highlighting the potential of specific dietary regimens prior to transplantation aiming for organ protection and the interplay between dietary intake and gut microbiota. Recent findings Nutrition holds the potential to optimize patients’ health prior to and after surgery, it may enhance patients’ ability to cope with the procedure-associated stress and it may accelerate their recovery from surgery. Nutrition helps to reduce morbidity and mortality in addition to preserve graft function. In the case of living organ donation, dietary preconditioning strategies promise novel approaches to limit ischemic organ damage during transplantation and to identify the underlying molecular mechanisms of diet-induced organ protection. Functioning gut microbiota are required to limit systemic inflammation and to generate protective metabolites such as short-chain fatty acids or hydrogen sulfide. Summary Nutritional intervention is a promising therapeutic concept including the pre- and rehabilitation stage in order to improve the recipients’ outcome after solid organ transplantation.

show abstract

Section: Cardiovascular Risk Reduction In the Long-term Maintenance P...mentioning

confidence: 99%

Fueling the success of transplantation through nutrition: recent insights into nutritional interventions, their interplay with gut microbiota and cellular mechanisms

Koehler,

Späth,

Meyer

et al. 2024

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

show abstract

“…However, randomized controlled trials found no adverse changes in lipid profiles after up to 24 months of tofacitinib treatment (Kuo et al, 2018;Sands et al, 2021). Given the increased risks of cardiovascular and other diseases linked to dyslipidemia (Zweifler et al, 2011;Zysset et al, 2016;Zuzda et al, 2022), clarifying the real-world effects of these widely used RA medications on blood lipids is clinically important.…”

Section: Introductionmentioning

confidence: 99%

Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients

Ma,

Shi,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

ObjectiveTo compare the effects of tofacitinib and adalimumab on the risk of adverse lipidaemia outcomes in patients with newly diagnosed rheumatoid arthritis (RA).MethodsData of adult patients newly diagnosed with RA who were treated with tofacitinib or adalimumab at least twice during a 3-year period from 1 January 2018 to 31 December 2020, were enrolled in the TriNetX US Collaborative Network. Patient demographics, comorbidities, medications, and laboratory data were matched by propensity score at baseline. Outcome measurements include incidental risk of dyslipidemia, major adverse cardiac events (MACE) and all-cause mortality.ResultsA total of 7,580 newly diagnosed patients with RA (1998 receiving tofacitinib, 5,582 receiving adalimumab) were screened. After propensity score matching, the risk of dyslipidaemia outcomes were higher in the tofacitinib cohort, compared with adalimumab cohort (hazard ratio [HR] with 95% confidence interval [CI], 1.250 [1.076–1.453]). However, there is no statistically significant differences between two cohorts on MACE (HR, 0.995 [0.760–1.303]) and all-cause mortality (HR, 1.402 [0.887–2.215]).ConclusionTofacitinib use in patients with RA may increase the risk of dyslipidaemia to some extent compared to adalimumab. However, there is no differences on MACE and all-cause mortality.

show abstract

Exploring the Effects of Hyperlipidemia in Kidney Transplantation

Zheng,

Zhao,

Jin

2024

Journal of Clinical Nursing

View full text Add to dashboard Cite

Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?

Cited by 3 publications

References 183 publications

Fueling the success of transplantation through nutrition: recent insights into nutritional interventions, their interplay with gut microbiota and cellular mechanisms

Fueling the success of transplantation through nutrition: recent insights into nutritional interventions, their interplay with gut microbiota and cellular mechanisms

Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients

Exploring the Effects of Hyperlipidemia in Kidney Transplantation

Contact Info

Product

Resources

About